Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2012

01-02-2012 | Original Article

A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)

Authors: Wasaburo Koizumi, Norisuke Nakayama, Satoshi Tanabe, Tohru Sasaki, Katsuhiko Higuchi, Ken Nishimura, Seiichi Takagi, Mizutomo Azuma, Takako Ae, Kenji Ishido, Kento Nakatani, Akira Naruke, Chikatoshi Katada

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2012

Login to get access

Abstract

Purpose

We conducted a phase II study to evaluate the efficacy and safety of a triplet regimen of docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer.

Methods

Docetaxel (40 mg/m2) and cisplatin (70 or 60 mg/m2) were given on day 1 of a 28-day cycle. S-1 (40 mg/m2) was given twice daily on days 1–14. Treatment with this regimen was continued for a maximum of 6 cycles. Subsequently, patients with no disease progression received a combination of docetaxel and S-1.

Results

Fifty-nine patients were enrolled. The median number of administered cycles was 8 (range, 1–25). Because some patients had serious myelosuppression and renal dysfunction with 70 mg/m2 of cisplatin, dose of cisplatin was reduced to 60 mg/m2 after 19 patients had been treated. Common severe toxic effects of grade 3 or 4 were leukocytopenia (44%), neutropenia (72%), anemia (15%), and febrile neutropenia (14%). The overall response rate of this group was 81% (95% confidence interval (CI), 71–91%). The median overall survival and progression-free survival were 18.5 (95% CI, 15.6–21.5) and 8.7 (95% CI, 6.7–10.7) months, respectively.

Conclusions

Triplet of docetaxel, cisplatin, and S-1 is a well-tolerated and highly active regimen for advanced or recurrent gastric cancer. A 60 mg/m2 of cisplatin is as effective as 70 mg/m2 of cisplatin.
Literature
1.
Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150PubMedCrossRef
2.
Munoz N, Franceschi S (1997) Epidemiology of gastric cancer and perspectives for prevention. Salud Publica Mex 39(4):318–330PubMed
3.
Ministry of Health Law. Vital Statistics of Japan (2009)
4.
Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548–557PubMedCrossRef
5.
Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10(11):1063–1069PubMedCrossRef
6.
Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221PubMedCrossRef
7.
Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V et al (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28(9):1547–1553PubMedCrossRef
8.
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24(31):4991–4997PubMedCrossRef
9.
Nakayama N, Koizumi W, Sasaki T, Higuchi K, Tanabe S, Nishimura K et al (2008) A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601). Oncology 75(1–2):1–7PubMedCrossRef
10.
Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y et al (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402–3407PubMedCrossRef
11.
Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H et al (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94(12):1803–1808PubMedCrossRef
12.
Fujii M (2008) Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol 13(3):201–205PubMedCrossRef
13.
Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S et al (2010) Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 66:721–728
14.
Al-Refaie WB, Tseng JF, Gay G, Patel-Parekh L, Mansfield PF, Pisters PWT, Yao JC, Feig BW (2008) The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Cancer 113:461–469PubMedCrossRef
Metadata
Title
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)
Authors
Wasaburo Koizumi
Norisuke Nakayama
Satoshi Tanabe
Tohru Sasaki
Katsuhiko Higuchi
Ken Nishimura
Seiichi Takagi
Mizutomo Azuma
Takako Ae
Kenji Ishido
Kento Nakatani
Akira Naruke
Chikatoshi Katada
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-011-1701-1

Other articles of this Issue 2/2012

Cancer Chemotherapy and Pharmacology 2/2012 Go to the issue

Original Article

Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study

Original Article

Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin

Original Article

A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies

Original Article

Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

Original Article

Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2

Original Article

Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits